75000 - Document - Document and Entity Information
link:presentationLink
link:calculationLink
link:definitionLink
75010 - Statement - CONSOLIDATED BALANCE SHEETS
link:presentationLink
link:calculationLink
link:definitionLink
75020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
75030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME
link:presentationLink
link:calculationLink
link:definitionLink
75040 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
link:presentationLink
link:calculationLink
link:definitionLink
75050 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS
link:presentationLink
link:calculationLink
link:definitionLink
75060 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance
link:presentationLink
link:calculationLink
link:definitionLink
995455 - Disclosure - Organization
link:presentationLink
link:calculationLink
link:definitionLink
995465 - Disclosure - Summary of Significant Accounting Policies
link:presentationLink
link:calculationLink
link:definitionLink
995475 - Disclosure - Revenue
link:presentationLink
link:calculationLink
link:definitionLink
995485 - Disclosure - Fair Value Measurements
link:presentationLink
link:calculationLink
link:definitionLink
995495 - Disclosure - Accrued Liabilities Detail
link:presentationLink
link:calculationLink
link:definitionLink
995505 - Disclosure - Property and Equipment, Net
link:presentationLink
link:calculationLink
link:definitionLink
995515 - Disclosure - Debt
link:presentationLink
link:calculationLink
link:definitionLink
995525 - Disclosure - Stockholders' Equity
link:presentationLink
link:calculationLink
link:definitionLink
995535 - Disclosure - Share-Based Compensation
link:presentationLink
link:calculationLink
link:definitionLink
995545 - Disclosure - Income Taxes
link:presentationLink
link:calculationLink
link:definitionLink
995555 - Disclosure - Commitments and Contingencies
link:presentationLink
link:calculationLink
link:definitionLink
995565 - Disclosure - Segment Information
link:presentationLink
link:calculationLink
link:definitionLink
995575 - Disclosure - Related Party Transactions
link:presentationLink
link:calculationLink
link:definitionLink
995585 - Disclosure - Subsequent Events
link:presentationLink
link:calculationLink
link:definitionLink
995595 - Disclosure - Summary of Significant Accounting Policies (Policies)
link:presentationLink
link:calculationLink
link:definitionLink
995605 - Disclosure - Summary of Significant Accounting Policies (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995615 - Disclosure - Revenue (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995625 - Disclosure - Accrued Liabilities Detail (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995635 - Disclosure - Property and Equipment, Net (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995645 - Disclosure - Debt (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995655 - Disclosure - Share-Based Compensation (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995665 - Disclosure - Income Taxes (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995675 - Disclosure - Commitments and Contingencies (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995685 - Disclosure - Segment Information (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995695 - Disclosure - Organization (Details Textual)
link:presentationLink
link:calculationLink
link:definitionLink
995705 - Disclosure - Summary of Significant Accounting Policies (Details Textual)
link:presentationLink
link:calculationLink
link:definitionLink
995715 - Disclosure - Summary of Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995725 - Disclosure - Revenue - Summary of Changes in Balances of Receivables and Contract Liability (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995735 - Disclosure - Revenue (Details Textual)
link:presentationLink
link:calculationLink
link:definitionLink
995745 - Disclosure - Revenue - Summary of Revenue (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995755 - Disclosure - Revenue - Schedule of Accounts Receivable (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995765 - Disclosure - Revenue (Details Textual 1)
link:presentationLink
link:calculationLink
link:definitionLink
995765 - Disclosure - Revenue (Details Textual 1) [Default]
link:presentationLink
link:calculationLink
link:definitionLink
995775 - Disclosure - Fair Value Measurements (Details Textual)
link:presentationLink
link:calculationLink
link:definitionLink
995785 - Disclosure - Accrued Liabilities Detail - Schedule of Accrued Liabilities (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995795 - Disclosure - Property and Equipment, Net - Summary of Components of Property and Equipment, Net (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995805 - Disclosure - Property and Equipment, Net (Details Textual)
link:presentationLink
link:calculationLink
link:definitionLink
995815 - Disclosure - Debt (Details Textual)
link:presentationLink
link:calculationLink
link:definitionLink
995825 - Disclosure - Stockholders' Equity (Details Textual)
link:presentationLink
link:calculationLink
link:definitionLink
995835 - Disclosure - Share-Based Compensation (Details Textual)
link:presentationLink
link:calculationLink
link:definitionLink
995845 - Disclosure - Share-Based Compensation (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995855 - Disclosure - Share-Based Compensation (Details 1)
link:presentationLink
link:calculationLink
link:definitionLink
995865 - Disclosure - Share-Based Compensation - (Details 2)
link:presentationLink
link:calculationLink
link:definitionLink
995875 - Disclosure - Share-Based Compensation (Details 3)
link:presentationLink
link:calculationLink
link:definitionLink
995885 - Disclosure - Income Taxes (Details 1)
link:presentationLink
link:calculationLink
link:definitionLink
995895 - Disclosure - Income Taxes (Details 2)
link:presentationLink
link:calculationLink
link:definitionLink
995905 - Disclosure - Income Taxes (Details 3)
link:presentationLink
link:calculationLink
link:definitionLink
995915 - Disclosure - Income Taxes (Details 4)
link:presentationLink
link:calculationLink
link:definitionLink
995925 - Disclosure - Income Taxes (Details 5)
link:presentationLink
link:calculationLink
link:definitionLink
995935 - Disclosure - Income Taxes (Details Textual)
link:presentationLink
link:calculationLink
link:definitionLink
995945 - Disclosure - Income Taxes (Details 6)
link:presentationLink
link:calculationLink
link:definitionLink
995955 - Disclosure - Commitments and Contingencies (Details Textual)
link:presentationLink
link:calculationLink
link:definitionLink
995965 - Disclosure - Commitments and Contingencies - Remaining Payments of Operating Lease Liability (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995975 - Disclosure - Commitments and Contingencies - Remaining Payments of Operating Lease Liability (Details) 2
link:presentationLink
link:calculationLink
link:definitionLink
995985 - Disclosure - Segment Information - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995995 - Disclosure - Segment Information - Summary of Reported Segment Revenues, Segment Loss and Income, and Significant Segment Expenses (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996005 - Disclosure - Segment Information - Summary of Reported Segment Revenues, Segment Loss and Income, and Significant Segment Expenses (Parenthetical) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996015 - Disclosure - Related Party Transactions - Equity-Method Investment (Details Textual)
link:presentationLink
link:calculationLink
link:definitionLink
Revenue recognition reserve target exclusivity period.
Revenue Recognition Reserve Target Exclusivity Period
Revenue recognition, reserve target exclusivity period
Segments [Domain]
Foreign
Income (Loss) from Continuing Operations before Income Taxes, Foreign
Billed Accounts Receivable
Billed accounts receivable.
Billed accounts receivable
Concentration Risk Type [Axis]
Concentration Risk Type
Deferred Tax Assets, Gross [Abstract]
Deferred tax assets:
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Foreign countries.
Foreign Countries [Member]
Foreign Countries [Member]
Effective Income Tax Rate Reconciliation Effects Of Cross Border Tax Laws Global Intangible Low Tax Income Percent
Effective income tax rate reconciliation effects of cross-border tax laws global intangible low-tax income percent
Effects of cross-border tax laws - Global intangible low-tax income percent
Accounts payable
Increase (Decrease) in Accounts Payable, Total
Increase (Decrease) in Accounts Payable
Accounts payable
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]
Non-cash investing activities
Plan Name [Axis]
Plan Name
Entity Current Reporting Status
Entity Current Reporting Status
Operating Expenses [Abstract]
Operating expenses:
Commitments and Contingencies Disclosure [Text Block]
Commitments and Contingencies
Common Stock, Shares Authorized
Common stock, shares authorized
Contra expense included in research and development expense.
Contra Expense Included In Research And Development Expense
Contra expense included in research and development expense
Vinbiocare.
Vinbiocare [Member]
Vinbiocare [Member]
Product and Service [Axis]
Product and Service
September two thousand and twenty one lease agreement.
September Two Thousand And Twenty One Lease Agreement [Member]
September 2021 Lease Agreement [Member]
Document Fiscal Period Focus
Document Fiscal Period Focus
COVID-19 vaccine development.
C O V I D Nineteen Vaccine Development [Member]
COVID-19 Vaccine Development [Member]
ASU 2023-09 [Member]
Accounting Standards Update 2023-09 [Member]
Revenue from Contract with Customer [Abstract]
Entity Shell Company
Entity Shell Company
Discovery Technologies [Member]
Discovery technologies.
Discovery Technologies [Member]
Employees and officers.
Employees And Officers [Member]
Employees and Officers [Member]
Right-of-use assets
Right-of-use assets
Increase Decrease Operating Lease, Right Of Use Asset
Increase decrease operating lease, right of use asset.
Segment Reporting, Policy [Policy Text Block]
Segment Information
Cash and Cash Equivalents, at Carrying Value, Total
Cash and Cash Equivalent
Cash and cash equivalents
Schedule of Maturities of Long-Term Debt [Table Text Block]
Schedule of Maturities of Long-term Debt
Operating Lease, Impairment Loss
Impairment of right-of-use assets
Impairment loss
Cybersecurity Risk Management, Strategy, and Governance [Abstract]
Common Stock, Shares, Issued
Common stock, shares issued
Purchase of common stock, shares
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]
Cybersecurity Risk Board of Directors Oversight [Text Block]
Asset Class [Domain]
Statement [Table]
Statement [Table]
Non-current Restricted cash
Restricted Cash, Noncurrent
Non-current restricted cash
Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions
Increase for current period tax positions
Right-of-use assets acquired through operating leases
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Grant date weighted average fair value
Deferred tax liabilities, right-of-use asset.
Deferred Tax Liabilities Right Of Use Asset
Right-of-use asset
Deferred Tax Asset, Valuation Allowance [Table]
Collaboration Partner Cure Vac entered into Co-Development Agreement.
Collaboration Partner Cure Vac Entered Into Co Development Agreement [Member]
Collaboration Partner Cure Vac Entered Into Co Development Agreement [Member]
Statement [Line Items]
Statement [Line Items]
Entity Filer Category
Entity Filer Category
Royalty payment term description.
Royalty Payment Term Description
Royalty payment term description
Liabilities and Equity
Total liabilities and stockholders’ equity
Debt Instrument [Line Items]
Debt Instrument [Line Items]
Long-Term Debt, Current Maturities, Total
Long-Term Debt, Current Maturities
Current portion of long-term debt
Repyament of Principal and Interest on Collateralized Term Loan
Repayment of principal and interest on collateralized term loan.
Repayament of principal and interest on collateralized term loan
Credit Concentration Risk [Member]
Credit Risk [Member]
Operating loss carryforwards expiration year.
Operating Loss Carryforwards Expiration Year
Operating Loss Carryforwards Expiration Year
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Weighted-Average Exercise Price, Exercisable - December 31, 2024
Long-Lived Tangible Asset [Axis]
Long-Lived Tangible Asset
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Valuation allowance change
Janssen.
Janssen [Member]
Janssen [Member]
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]
One Big Beautiful Bill Act [Member]
One big beautiful bill act.
Commitment and contingencies.
Commitment And Contingencies [Line Items]
Commitment And Contingencies [Line Items]
Proceeds from Issuance of Debt
Proceeds from debt
Option to purchase of additional shares of common stock price per share.
Option To Purchase Of Additional Shares Of Common Stock Price Per Share
Purchase of additional shares of common stock price per share
Valuation allowance
Deferred Tax Assets, Valuation Allowance
Valuation allowance
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent
Federal statutory income tax rate percent
Cybersecurity Risk Management Third Party Engaged [Flag]
Documents Incorporated by Reference [Text Block]
Documents incorporated by reference
General and Administrative Costs Policy [Policy Text Block]
General and administrative costs.
General and Administrative Costs
Other non-cash expenses
Other Noncash Income (Expense), Total
Other Noncash Income (Expense)
Other non-cash expenses
Effective Income Tax Rate Reconciliation, Percent
Provision for income taxes
Income Tax Jurisdiction [Axis]
Income Tax Authority
LUNAR-OTC [Member]
LUNAR-OTC.
LUNAR-OTC [Member]
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration
Geographical [Domain]
Geographical
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]
Restricted Cash
Milestone payments
Milestone payments.
Milestone Payments
Collaboration agreement contractual term.
Collaboration Agreement Contractual Term
Contractual term
Upfront fee received.
Upfront Fee Received
Upfront fee received
Accounts Receivable, Allowance for Credit Loss, Ending Balance
Accounts Receivable, Allowance for Credit Loss, Beginning Balance
Accounts Receivable, Allowance for Credit Loss
Allowance for Doubtful Accounts Receivable
Additional financial support
Additional financial support
Liquidity.
Liquidity Policy Policy [Text Block]
Liquidity
Stock issued during period value under equity plan.
Stock Issued During Period Value Under Equity Plan
Issuance of common stock under equity plans
Significant Accounting Policies [Text Block]
Summary of Significant Accounting Policies
Property, Plant and Equipment [Line Items]
Property Plant And Equipment [Line Items]
Schedule of Cash and Cash Equivalents [Table Text Block]
Schedule of Cash and Cash Equivalents and Restricted Cash
Vesting [Domain]
Vesting
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross
Number of Shares, Granted
Disaggregation of Revenue [Table]
Disaggregation Of Revenue [Table]
Cybersecurity Risk Management, Strategy, and Governance [Table]
Clinical trial accruals current.
Clinical Trial Accruals Current
Clinical trial accruals
Investment, Name [Axis]
Investment, Name
Basic
Earnings Per Share, Basic
Earnings Per Share, Basic, Total
Disaggregation of Revenue [Table Text Block]
Schedule of Revenue
Repayment of term loan
Repayments of Long-Term Debt
Repayments of Long-Term Debt, Total
Contract with customer asset additions for revenue recognized.
Contract With Customer Asset Additions For Revenue Recognized
Contract Assets, Additions for revenue recognized from billings
Non-rare disease targets.
Non Rare Disease Targets [Member]
Non-Rare Disease Targets [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Number of Shares, Outstanding
Number of Shares, Outstanding
Liabilities, Current
Total current liabilities
Cash pledged as collateral released
Cash Pledged As Collateral Released
Cash pledged as collateral released.
Cystic Fibrosis Foundation Therapeutics, Inc.
Cystic Fibrosis Foundation Therapeutics Inc [Member]
Cystic Fibrosis Foundation [Member]
Increase (Decrease) in Accounts Receivable
Accounts receivable
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]
Adjustments to reconcile net loss to net cash used in operating activities:
Lessee, Operating Lease, Liability, to be Paid, Year Five
2030
CSL Collaboration Agreement [Member]
CSL Collaboration Agreement.
Income Tax Paid, Federal, after Refund Received
Income Tax Paid, Federal, after Refund Received, Total
Federal income taxes paid, net of (refunds) received
Domestic Tax Jurisdiction [Member]
Federal [Member]
Accounting Standards Update [Axis]
Accounting Standards Update
Equity, Attributable to Parent [Abstract]
Stockholders’ equity:
Inventory, Cash Flow Policy [Policy Text Block]
Statement of Cash Flows
Entity Small Business
Entity Small Business
Payments for matching funds for remaining budgeted costs.
Payments For Matching Funds For Remaining Budgeted Costs
Payments for matching funds for remaining budgeted costs
Increase (Decrease) in Accrued Liabilities, Total
Increase (Decrease) in Accrued Liabilities
Accrued liabilities
Retained Earnings (Accumulated Deficit), Total
Retained Earnings (Accumulated Deficit)
Accumulated deficit
Accumulated deficit
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost
Share-based compensation
Entity Well-known Seasoned Issuer
Entity Well-known Seasoned Issuer
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Number of Shares, Forfeited/cancelled
Sale of Stock, Price Per Share
weighted-average price per share
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value
Aggregate Intrinsic Value, Exercised
The total intrinsic value of options exercised
Foreign
Current Foreign Tax Expense (Benefit)
Share-Based Payment Arrangement [Text Block]
Share-Based Compensation
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ARCALIS [Member]
ARCALIS.
Lease Contractual Term [Axis]
Leases [Abstract]
Deferred revenue, Balance
Deferred revenue, Balance
Contract with Customer, Liability, Total
Contract with Customer, Liability
Deferred revenue
February two thousand and twenty lease agreement.
February Two Thousand And Twenty Lease Agreement [Member]
February 2020 Lease Agreement [Member]
Revenue.
Revenue [Line Items]
Revenue [Line Items]
Amendment Flag
Amendment Flag
Product and Service [Domain]
Product and Service
CSL [Member]
CSL [Member]
CSL.
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
U.S. federal statutory rate
Exercise of warrants for shares of common stock
Class of Warrant or Right, Number of Securities Called by Warrants or Rights
Earnings Per Share, Policy [Policy Text Block]
Net Loss per Share
Number Of Reportable Segments Not Disclosed Flag
Number of reportable segments not disclosed flag.
Liabilities and Stockholders' Equity
Liabilities and Equity [Abstract]
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
Option exercise revenue range per target.
Option Exercise Revenue Range Per Target
Option exercise revenue range per target
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Net cash used in operating activities
Lease liabilities
Lease liabilities
Increase (Decrease) in Operating Lease Liability
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description
Disbursement period three.
Disbursement Period Three [Member]
Disbursement Due July 2020 [Member]
Common Stock [Member]
Common Stock [Member]
Cybersecurity Risk Role of Management [Text Block]
Reserved upfront payment
Reserved Upfront Payment
Reserved upfront payment.
Tax Credit Carryforward, Amount
Credit Carryforward Amount
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Weighted-Average Exercise Price, Granted
Lessee, Operating Lease, Liability, to be Paid, Year Three
2028
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Less accumulated depreciation and amortization
Payments to Acquire Interest in Joint Venture
Cash consideration paid for equity interest in joint venture
Research Collaboration and Exclusive License Agreement.
Research Collaboration And Exclusive License Agreement [Member]
Research Collaboration And Exclusive License Agreement [Member]
Business Description and Accounting Policies [Text Block]
Organization
Debt Instrument, Interest Rate, Effective Percentage
Loan accrues interest rate per annum, percentage
Entity Address, Address Line One
Entity Address, Address Line One
Total gross deferred tax liabilities
Total gross deferred tax liabilities
Deferred Tax Liabilities, Gross
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]
Change in accounting principle, accounting standards update, immaterial effect [true false]
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
Schedule of Weighted Average Assumptions Used in Black -Scholes Valuation Model
Fair Value Hierarchy and NAV [Axis]
BARDA [Member]
Biomedical Advanced Research and Development Authority [Member]
Biomedical Advanced Research and Development Authority.
Earnings Per Share [Abstract]
Net loss per share
Income Tax, Policy [Policy Text Block]
Income Tax Expense
Collaboration agreement transaction price.
Collaboration Agreement Transaction Price
Transaction price
Gross Proceeds from Issuance of Common Stock
Gross proceeds from issuance of common stock.
Gross proceeds from sale of common stock
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]
Supplemental disclosure of cash flow information
Supplemental Cash Flow Information [Abstract]
Thereafter
Lessee Operating Lease Liability Payments Due After Year Four
Lessee operating lease liability payments due after year four.
Operating Lease, Right-of-Use Asset
Operating lease right-of-use asset, net
Operating lease right-of-use asset
Deferred Tax Assets, Gross
Total gross deferred tax assets
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]
Document Type
Document Type
Wells Fargo Credit Agreement [Member]
Wells fargo credit agreement.
Wells Fargo Credit Agreement Member
Cash paid for income taxes
Income Taxes Paid, Net
Total income taxes paid, net of (refunds) received
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative
COVID vaccination age limit
COVID Vaccination Age Limit
COVID vaccination age limit.
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Collaborative Arrangement and Arrangement Other than Collaborative
Loan and security agreement.
Loan And Security Agreement [Member]
Loan and Security Agreement [Member]
Entity Central Index Key
Entity Central Index Key
Early-Stage Programs [Member]
Early-Stage Programs [Member]
Early-Stage Programs.
Payments for (Proceeds from) Tenant Allowance
Tenant improvement allowance
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]
Realized Gain (Loss), Foreign Currency Transaction, before Tax
Foreign currency transaction loss
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Net decrease in cash, cash equivalents and restricted cash
Subsequent Event Type [Domain]
Subsequent Event Type
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Antidilutive securities excluded from computation of earnings per share
Deferred Tax Assets, Equity Method Investments
Basis difference in equity investments
Common Stock, Par or Stated Value Per Share
Common stock, par value
Accounting Standards Update [Domain]
Accounting Standards Update
Effective income tax rate reconciliation nondeductible expense officers compensation.
Effective Income Tax Rate Reconciliation Nondeductible Expense Officers Compensation
Officers compensation
Security Deposit
Security deposit
Payroll and Benefits [Member]
Payroll and benefits.
Payroll and Benefits [Member]
Share-Based Payment Arrangement, Tranche One [Member]
First Year Anniversary of the Grant [Member]
Option exercise fee revenue received.
Option Exercise Fee Revenue Received
Option exercise fee received
Weighted-Average Remaining Contractual Term (Years), Outstanding
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term
Adjustments to transaction price.
Adjustments To Transaction Price
Adjustments to transaction price
Document Financial Statement Error Correction
Document Financial Statement Error Correction [Flag]
Issuance of common stock upon exercise of stock options (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period
Number of Shares, Exercised
Contract with customer asset deductions for cash collections.
Contract With Customer Asset Deductions For Cash Collections
Contract Assets, Deductions for cash collections
Debt Disclosure [Abstract]
Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities
Settlement of prior period tax positions
Number of Business Segment
Number of business segment.
Number of business segment
Ultragenyx.
Ultragenyx [Member]
Ultragenyx [Member]
Accrued Liabilities, Current
Accrued liabilities
Total
Development and option agreement date.
Development And Option Agreement Date
Development and option agreement date
Current Fiscal Year End Date
Current Fiscal Year End Date
Schedule of Long-Term Debt Instruments [Table]
Debt Instrument [Table]
Concentration risk number of customer.
Concentration Risk Number Of Customer
Number of customers
Additional payments upon meeting certain clinical milestones.
Additional Payments upon Meeting Certain Clinical Milestones
Additional payments upon meeting certain clinical milestones
CALIFORNIA
California [Member]
Entity Address, State or Province
Entity Address, State or Province
Contra expense remaining amount included in accrued expenses.
Contra Expense Remaining Amount Included In Accrued Expenses
Contra expense remaining amount included in accrued expenses
Number of Shares Outstanding, Beginning Balance
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Number of Shares Outstanding, Ending Balance
Investment, Name [Domain]
Investment, Name
Investment Owned, Balance, Shares
Number of shares owned
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive loss
Research and Development Expense, Policy [Policy Text Block]
Research and Development Costs, net
Common Stock, Capital Shares Reserved for Future Issuance
Common stock reserved for future issuance
Geographical [Axis]
Geographical
Revenue recognized
Deductions
Contract with Customer, Liability, Revenue Recognized
Accounts Receivable [Member]
Accounts Receivable [Member]
State and local income taxes, net of federal income tax effect
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
Other
Stock Issued During Period, Value, Stock Options Exercised
Issuance of common stock upon exercise of stock options
Comprehensive Income, Policy [Policy Text Block]
Comprehensive Loss
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
Significant Components of Deferred Income Taxes
Subsequent Event [Member]
Subsequent Event [Member]
Equity Method Investment, Nonconsolidated Investee [Domain]
Equity Method Investment, Nonconsolidated Investee
SGI.
S G I [Member]
SGI [Member]
Deferred Revenue, Current, Total
Deferred Revenue, Current
Deferred revenue
Property, Plant and Equipment [Abstract]
October 2017 lease amendment.
October Two Thousand And Seventeen Lease Amendment [Member]
October 2017 Lease Amendment [Member]
Deferred Tax Assets, Inventory
Inventory
Antidilutive Securities [Axis]
Antidilutive Securities
Summary of significant accounting policy.
Summary Of Significant Accounting Policy [Line Items]
Summary Of Significant Accounting Policy [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage
Vesting percentage
Income Tax Paid, Foreign, after Refund Received
Income Tax Paid, Foreign, after Refund Received, Total
Foreign income taxes paid, net of (refunds) received
Western Alliance Bank.
Western Alliance Bank [Member]
Western Alliance Bank [Member]
Option to purchase of additional shares of common stock.
Option To Purchase Of Additional Shares Of Common Stock
Purchase of additional shares of common stock
State and Local Jurisdiction [Member]
State [Member]
Share-Based Payment Arrangement, Cost by Plan [Table Text Block]
Schedule of Share-based Compensation Expenses
Disbursement Period Two [Member]
Disbursement Due April 2020 [Member]
Disbursement period two.
Goodwill, Impairment Loss
Impairment losses
Facilities and Equipment [Member]
Facilities and equipment.
Facilities and Equipment [Member]
Lessee, Operating Lease, Option to Extend
Lessee, operating leases, option to extend
Impairment loss
Deferred tax assets property, plant and equipment and intangible assets.
Deferred Tax Assets Property Plant And Equipment And Intangible Assets
Depreciation and amortization
COVID-19 Vaccine [Member]
COVID-19 vaccine.
Other.
Other [Member]
Other [Member]
Deferred:
Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]
Gates Foundation [Member]
Gates Foundation
Debt Instrument, Maturity Date
Loan maturity date
Underwritten public offering.
Underwritten Public Offering [Member]
Underwritten Public Offering [Member]
Minimum [Member]
Minimum [Member]
Assets, Current [Abstract]
Current assets:
Income taxes.
Income Taxes [Table]
Income Taxes [Table]
Rare disease targets.
Rare Disease Targets [Member]
Rare Disease Targets [Member]
Segment Reporting [Abstract]
Tax Period [Domain]
Liabilities, Current [Abstract]
Current liabilities:
Revenue recognition potential milestone revenue recognized.
Revenue Recognition Potential Milestone Revenue Recognized
Revenue recognition potential milestone revenue recognized
Development milestones due
Development Milestones Amount Due for Agreement
Development milestones amount due for agreement.
2021 Inducement equity incentive plan.
Twenty Twenty One Inducement Equity Incentive Plan [Member]
2021 Inducement Equity Incentive Plan [Member]
Eligible to receive development milestone payment
Eligible to Receive Development Milestone Payment
Eligible to Receive Development Milestone Payment
Related Party Transactions [Abstract]
Total grant revenue
Grant Revenue
Grant revenue.
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities
Accrued liabilities
Shares, Outstanding
Balance (in shares)
Balance (in shares)
Operating Loss Carryforwards
Operating Loss Carryforwards
Accounts Receivable, after Allowance for Credit Loss, Current
Accounts receivable
Total accounts receivable
Total accounts receivable
Lessee, Operating Lease, Renewal Term
Operating lease extended additional term
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax, Total
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax
Income tax effect related to unrealized losses on marketable securities
Proceeds from Stock Plans
Proceeds from issuance of common stock under equity plans
Lessee, Leases [Policy Text Block]
Leases
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Weighted- Average Grant Date Fair Value, Outstanding, Beginning Balance
Weighted- Average Grant Date Fair Value, Outstanding, Ending Balance
General and Administrative Expense [Member]
General and Administrative [Member]
Operating Lease, Liability, Total
Operating Lease, Liability
Total operating lease liabilities
Auditor Firm ID
Auditor Firm ID
Floating interest rate
Debt Instrument, Basis Spread on Variable Rate
Interest of the prime rate plus
Forecast [Member]
Deferred tax assets property, plant and equipment and intangible assets.
Deferred Tax Liabilities Property Plant And Equipment And Intangible Assets
Depreciation and amortization
Restricted Cash, Current
Restricted cash - current
Restricted cash
Development milestones received advance payment
Development milestones received advance payment.
Development Milestones Received Advance Payment
Concentration Risk Benchmark [Axis]
Concentration Risk Benchmark
Effective income tax rate reconciliation uncertain tax position.
Effective Income Tax Rate Reconciliation Uncertain Tax Position
Uncertain tax position
Potential target license term.
Potential Target License Term
Potential target license term
manufacturing and supply of ARCT-154 drug product.
Manufacturing and Supply of ARCT-154 Drug Product [Member]
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent
Change in valuation allowance percent
Purchase of property and equipment in accounts payable and accrued expenses
Capital Expenditures Incurred but Not yet Paid
Lease Contractual Term [Domain]
Percentage Of First Year Bonus Depreciation
Percentage of first year bonus depreciation.
Percentage of first year bonus depreciation
Number of reserved vaccine doses.
Number Of Reserved Vaccine Doses
Number of reserved vaccine doses
Pre-launch inventory policy.
Pre Launch Inventory Policy Policy [Text Block]
Pre-Launch Inventory
Long-Term Debt, Type [Domain]
Long-term Debt, Type
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]
Basic
Weighted Average Number of Shares Outstanding, Basic
Weighted Average Number of Shares Outstanding, Basic, Total
Achieved development milestone included accounts receivable.
Achieved development milestone included accounts receivable
Achieved development milestone included accounts receivable
Scenario [Axis]
Scenario
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value
Aggregate Intrinsic Value, Exercisable - December 31, 2024
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Segments [Axis]
Long-Lived Tangible Asset [Domain]
Long-Lived Tangible Asset
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]
Subsequent Events
Subsequent Events [Text Block]
Long-Term Debt
Long-term debt
Total
Related Party Transactions Disclosure [Text Block]
Related Party Transactions
Upfront payment received.
Upfront Payment Received
Upfront payment received
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
Share-based compensation
Variable Rate [Domain]
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount
Changes in valuation allowance
Equity, Attributable to Parent
Balance
Balance
Total stockholders’ equity
Statement of Stockholders' Equity [Abstract]
Tax credit carryforward expiration year.
Tax Credit Carryforward Expiration Year
Credit Carryforward Expiration Year
Equity Method Investments
Equity-method investment
Revenue.
Revenue [Table]
Revenue [Table]
Unvested restricted ordinary shares.
Unvested Restricted Ordinary Shares [Member]
Unvested Restricted Ordinary Shares [Member]
Collaboration agreement consideration received.
Collaboration Agreement Consideration Received
Consideration received
Leasehold Improvements [Member]
Leasehold improvements [Member]
Foreign currency transaction (loss) gain
Foreign Currency Transaction Gain (Loss), before Tax, Total
Foreign currency transaction gain
Gain (loss) from foreign currency
ADAIR Technology.
A D A I R Technology [Member]
ADAIR Technology [Member]
Entity Address, Address Line Two
Entity Address, Address Line Two
Fair Value Disclosures [Text Block]
Fair Value Measurements
Seqirus Agreement [Member]
Seqirus Agreement [Member]
Seqirus Agreement.
February two thousand and twenty one lease agreement.
February Two Thousand And Twenty One Lease Agreement [Member]
February 2021 Lease Agreement [Member]
Recognized contra expense.
Recognized Contra Expense
Contra expense
Contra research and development expense.
Contra Research And Development Expense
Contra research and development expense recognized
UNITED STATES
United States [Member]
Research collaboration and license agreement.
Research Collaboration And License Agreement [Member]
Research Collaboration And License Agreement [Member]
Additional clinical milestone payment
Additional clinical milestone payment
Number of performance obligations.
Number Of Performance Obligations
Number of performance obligations
Schedule of Accrued Liabilities [Table Text Block]
Schedule of Accrued Liabilities
Debt Instrument, Collateral Amount
Debt instrument, collateral amount
Income Tax Reconciliation [Line Items]
Income tax reconciliation.
Additions
Contract With Customer Liability Additions
Contract with customer liability additions.
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]
Summary of Reconciliation of Unrecognized Tax Benefits
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]
Other
Segment Reporting, Other Segment Item, Amount
Other
Plan Name [Domain]
Plan Name
Keith C. Kummerfeld [Member]
Keith C. Kummerfeld.
Keith C. Kummerfeld [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Receivable [Policy Text Block]
Accounts Receivable
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date
Equity Method Investment, Ownership Percentage
Equity method ownership percentage
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price
Weighted-Average Exercise Price, Exercisable and expected to vest -December 31, 2024
State
Current State and Local Tax Expense (Benefit)
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights
Vesting description
Tax Period [Axis]
Agreement amount agreed to fund.
Agreement Amount Agreed To Fund
Amount agreed to fund
Related and Nonrelated Parties [Axis]
Related Party
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount
Other
Property, Plant and Equipment, Policy [Policy Text Block]
Property and Equipment, net
Entity Address, City or Town
Entity Address, City or Town
Security Exchange Name
Security Exchange Name
Other percent
Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
Property, Plant and Equipment, Gross, Ending Balance
Property, Plant and Equipment, Gross, Beginning Balance
Property, Plant and Equipment, Gross, Total
Property, Plant and Equipment, Gross
Property and equipment, gross
Current:
Current Income Tax Expense (Benefit), Continuing Operations [Abstract]
Grant one.
Grant One [Member]
Grant 1 [Member]
Vinbiocare contractual liabilities
Vinbiocare Contractual Liabilities
Vinbiocare contractual liabilities.
Counterparty Name [Axis]
Counterparty Name
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Net loss before income taxes
Concentration Risk Type [Domain]
Concentration Risk Type
Upfront consideration received
Upfront Consideration Received
Upfront consideration received.
Number of reserve targets.
Number Of Reserve Targets
Number of targets
CureVac AG.
Cure Vac A G [Member]
CureVac [Member]
Contract with Customer, Duration [Domain]
Antidilutive Securities, Name [Domain]
Antidilutive Securities, Name
Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals Inc [Member]
Alexion [Member]
Stockholders' Equity Note [Abstract]
Cash, cash equivalents and restricted cash, end of year
Cash, cash equivalents and restricted cash, beginning of year
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation
Cash and cash equivalents, including restricted cash
Total cash, cash equivalents and restricted cash shown in the statement of cash flows
Interest Paid, Excluding Capitalized Interest, Operating Activity
Cash paid for interest
Statistical Measurement [Domain]
Statistical Measurement
Grant revenue outstanding
Grant Revenue Outstanding
Grant revenue outstanding.
Share price
Class of Warrant or Right, Exercise Price of Warrants or Rights
Assets, Current
Total current assets
Share-Based Payment Arrangement, Expense
Share-based compensation expenses
Share-based compensation expenses
Document Period End Date
Document Period End Date
Upfront fee/consideration.
Upfront Fee And Consideration
Upfront fee/consideration
Title and Position [Axis]
Title of Individual
Fair Value Hierarchy and NAV [Domain]
ICFR Auditor Attestation Flag
ICFR Auditor Attestation Flag
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number
Number of Shares, Exercisable December 31, 2024
Line of Credit Facility, Commitment Fee Percentage
Non-refundable commitment fee, percentage
Not Subject to Expiration [Member]
Not subject to expiration.
Maximum percentage of likelihood of uncertain tax position recognized to be sustained.
Maximum Percentage Of Likelihood Of Uncertain Tax Position Recognized To Be Sustained
Maximum percentage of likelihood of uncertain tax position recognized to be sustained
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]
Statement of Financial Position [Abstract]
Vallon Pharmaceuticals, Inc.
Vallon Pharmaceuticals Inc [Member]
Vallon Pharmaceuticals, Inc. [Member]
Restricted Stock Units (RSUs) [Member]
Restricted Stock Units [Member]
Cumulative Effect, Period of Adoption, Adjustment [Member]
Cumulative Effect, Period of Adoption, Adjustment [Member]
Loss Contingency Nature [Axis]
Decrease for prior period tax positions
Unrecognized tax benefits (decreases) increases resulting from prior period tax positions.
Unrecognized Tax Benefits Decreases Increases Resulting From Prior Period Tax Positions
(Decrease) increase for prior period tax positions
(Decrease) Increase for prior period tax positions
Revenue [Policy Text Block]
Revenue Recognition
Loss Contingency, Nature [Domain]
Vesting [Axis]
Vesting
Net Instrument Collateral Amount Released
Net instrument collateral amount released.
Current Income Tax Expense (Benefit)
Total current income tax (benefit) expense
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent
Change in tax rate
Liabilities
Total liabilities
Minimum amount agreed to incur under research plan.
Minimum Amount Agreed to Incur Under Research Plan
Minimum amount agreed to incur under research plan
Monthly base rent.
Monthly Base Rent
Monthly base rent
Dividends, Total
Dividends
Dividends declared or paid
Lessee, Operating Lease, Liability, to be Paid, Year Two
2027
Lack of marketability discount restricted period.
Lack Of Marketability Discount Restricted Period
Lack of marketability discount restricted period
Variable Rate [Axis]
ILLINOIS
Israeli Ministry of Health ("MOH") [Member]
Diluted
Weighted Average Number of Shares Outstanding, Diluted
Weighted Average Number of Shares Outstanding, Diluted, Total
Entity File Number
Entity File Number
Other accrued research and development expenses.
Other Accrued Research And Development Expenses
Other accrued research and development expenses
Accounting Standards Update 2023-07 [Member]
ASU 2023-07 [Member]
Cover [Abstract]
Cover
Cumulative Effect, Period of Adoption [Axis]
Cumulative Effect, Period of Adoption
Income tax payable
Taxes Payable, Current
Taxes Payable, Current, Total
Property Lease Guarantee [Member]
Property Leases in San Diego [Member]
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest
Total (loss) income before income taxes
SINGAPORE
Singapore Economic Development Board [Member]
Singapore Loan [Member]
Revenue Benchmark [Member]
Revenue [Member]
Scenario [Domain]
Scenario
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized
Share-based compensation number of shares authorized
Number of Operating Segments
Number of operating segments for research and development
Sale of Stock [Domain]
Sale of Stock
Segment Reporting Disclosure [Text Block]
Segment Information
General and Administrative Expense, Total
General and Administrative Expense
General and administrative
General and administrative
Contract with Customer, Duration [Axis]
Foreign Jurisdictions Filing Tax Returns Years
Foreign jurisdictions filing tax returns years.
Foreign jurisdictions filing tax returns period
Stock Issued During Period, Shares, Acquisitions
Issuance of common stock related to acquired in-process research and development (in shares)
Disbursement period four.
Disbursement Period Four [Member]
Disbursement Due October 2020 [Member]
Line of Credit Facility, Interest Rate During Period
Loans interest rate, percentage
Summary Of Income Taxes Paid Net Of Refunds Received [Table Text Block]
Summary of income taxes paid, net of refunds received.
Summary Of Income Taxes Paid Net of (Refunds) Received
Gain (Loss) on Extinguishment of Debt, Total
Gain (Loss) on Extinguishment of Debt
Gain on debt extinguishment
Gain on debt extinguishment
Property, Plant and Equipment, Useful Life
Property and equipment, useful lives
New Accounting Pronouncements, Policy [Policy Text Block]
Recently Adopted Accounting Pronouncements and Recently Issued Accounting Standards Not Yet Adopted
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]
Remaining Payments of Operating Lease Liability
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent
Other percent
Additions
Contract With Customer Asset Additions
Contract with customer asset additions.
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period
Vesting period
Debt instrument option for renewal term.
Debt Instrument Option for Renewal Term
Option for renewal term
Conditional payment
Conditional Payment
Conditional payment.
Net operating loss and research and development credit carryforwards limitations on cumulative change in ownership period.
Net Operating Loss And Research And Development Credit Carryforwards Limitations On Cumulative Change In Ownership Period
Net Operating Loss and Research and Development Credit Carryforwards Limitations on Cumulative Change In Ownership Period
Income (Loss) from Continuing Operations before Income Taxes, Domestic
United States
Development milestones achieved
Development milestones achieved.
Development Milestones Achieved
Short-Term Contract with Customer [Member]
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
Lessee, Operating Lease, Term of Contract
Lessee, operating lease, term of contract
Common Stock, Shares, Outstanding, Ending Balance
Common Stock, Shares, Outstanding, Beginning Balance
Common Stock, Shares, Outstanding
Common stock, shares outstanding
Operating Lease, Liability, Current
Current portion of operating lease liability
Revenue, Remaining Performance Obligation, Amount
Remaining performance obligation
Two Thousand Twenty Employee Stock Purchase Plan.
Two Thousand Twenty Employee Stock Purchase Plan [Member]
2020 Employee Stock Purchase Plan [Member]
Cybersecurity Risk Management Processes Integrated [Flag]
Document Transition Report
Document Transition Report
Reversal of revenue
Reversal of Revenue
Reversal of revenue.
Deferred Tax Assets, Net
Net deferred tax asset
Operating Expenses
Total operating expenses
Accrued Liabilities, Current [Abstract]
Research and Development Expense, Total
Research and Development Expense
Research and development, net
Total research and development
Total research and development
Orphan drug credit.
Orphan Drug Credit [Member]
Orphan Drug Credit [Member]
Remaining loan including accrued interest forgiveable
Remaining Loan Including Accrued Interest Forgiveable
Remaining loan including accrued interest forgiveable.
Effective Income Tax Rate Reconciliation Nondeductible Expense Limitations On Deductibility Of Officer Compensation
Effective income tax rate reconciliation nondeductible expense limitations on deductibility of officer Compensation.
Limitations on the deductibility of officer compensation
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
Summary of Reconciliation of Income Tax (Benefit) Expense
Statement of Cash Flows [Abstract]
Federal
Current Federal Tax Expense (Benefit)
Stock Issued During Period, Value, New Issues
Proceeds from issuance of common stock, net of issuance costs
Common stock issued, value
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
Summary of Share Option Activity
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent
Stock-based compensation percent
Equity [Text Block]
Stockholders' Equity
Organization and significant accounting policies.
Organization And Significant Accounting Policies [Table]
Organization And Significant Accounting Policies [Table]
Percentage of equity interest in joint venture.
Percentage Of Equity Interest In Joint Venture
Percentage of equity interest in joint venture
Unrecognized Tax Benefits that Would Impact Effective Tax Rate
Unrecognized tax benefits impacting effective tax rate
Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]
Summary of Restricted Stock Unit, Activity
Computer Equipment [Member]
Computer and software [Member]
Cybersecurity Risk Management Processes Integrated [Text Block]
Sale of Stock, Consideration Received Per Transaction
Consideration received for common stock purchase
Net income (loss)
Net loss
Net loss
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Aggregate Intrinsic Value, Outstanding
Net profits percentage
Percentage Of Net Profits
Percentage of net profits.
Operating Lease, Cost
Operating lease costs
Vinbiocare agreement.
Vinbiocare Agreement [Member]
Vinbiocare Agreement [Member]
Lance Kurata [Member]
Lance Kurata.
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Expected dividend yield
Accrued Facilities Costs Current
Accrued facilities costs current
Accrued facilities costs
Organization and significant accounting policies line items.
Organization And Significant Accounting Policies [Line Items]
Organization And Significant Accounting Policies [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value
Aggregate Intrinsic Value, Exercisable and expected to vest - December 31, 2024
Assets [Abstract]
Assets
Income Tax Authority, Name [Axis]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Risk-free interest rate
Construction in Progress [Member]
Construction in progress [Member]
Prepaid expenses and other current assets
Increase (Decrease) in Prepaid Expense and Other Assets
Repayments of Debt
Payments on debt obligations
Document Fiscal Year Focus
Document Fiscal Year Focus
Right-of-use lease liability
Deferred Tax Assets Right-of-use Lease Liability
Deferred tax assets right-of-use lease liability.
Borrowings under Guaranteed Investment Agreements
Term loan draw down
Concentration Risk Benchmark [Domain]
Concentration Risk Benchmark
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period
Remaining research period
Remaining period
Investing activities
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]
Accounts Payable, Current, Total
Accounts Payable, Current
Accounts payable
LUNAR-CF.
L U N A R C F [Member]
LUNAR-CF [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value
Fair value of options vested
Interest Expense, Long-Term Debt, Total
Interest Expense, Long-Term Debt
Interest expense related to long-term debt
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]
Summary of Reconciliation of (Loss) Income Before Income Taxes for Domestic and Foreign Locations
Research and Development Expense [Member]
Research and Development [Member]
ASU 2019-12 [Member]
Accounting Standards Update 2019-12 [Member]
Acquired In Process Research And Development Expense
Acquired In Process Research And Development Expense
Acquired in-process research and development expense
Non-cash charge recorded in acquired in-process research and development expense
Summary of Changes in Balances of Receivables and Contract Liability
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]
Federal
Deferred Federal Income Tax Expense (Benefit)
Development and Regulatory Milestones Achieved
Development and regulatory milestones achieved.
Development and regulatory milestones achieved
Research Tax Credit Carryforward [Member]
Research Tax Credit Carryforward [Member]
Reduction in number of common stock shares available for future issuance
Reduction in Number of Common Stock Capital Shares Available for Future Issuance
Reduction in number of common stock capital shares available for future issuance.
Research and development credits
Effective Income Tax Rate Reconciliation Research and Development Credits
Effective income tax rate reconciliation research and development credits.
Fair Value Measurement, Policy [Policy Text Block]
Fair Value Measurements
Unrecognized Tax Benefits [Roll Forward]
Proceeds from Stock Options Exercised
Proceeds from exercise of stock options
Fair Value Disclosures [Abstract]
Commitments and Contingencies Disclosure [Abstract]
Stock Issued During Period, Value, Acquisitions
Issuance of common stock related to acquired in-process research and development
Lessee, Operating Lease, Liability, to be Paid, Year One
2026
Investment Owned, Net Assets, Percentage
Percentage of owned shares
Phase I clinical study.
Phase I Clinical Study [Member]
Phase I Clinical Study [Member]
Lessee, Operating Lease, Liability, to be Paid, after Year Five
Thereafter
Two thousand nineteen omnibus incentive plan.
Two Thousand Nineteen Omnibus Incentive Plan [Member]
2019 Omnibus Equity Incentive Plan [Member]
Share-Based Payment Arrangement [Abstract]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
Compensation cost not yet recognized
Assets, Fair Value Disclosure, Total
Assets, Fair Value Disclosure
Assets, fair value
Pharmaceutical company.
Pharmaceutical Company [Member]
Pharmaceutical Company [Member]
Sale of Stock [Axis]
Sale of Stock
Concentration Risk, Percentage
Concentration risk, percentage
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Net cash used in investing activities
Eligible to receive commercial milestone payment
Eligible to Receive Commercial Milestone Payment
Eligible to receive commercial milestone payment.
Private Placement [Member]
Private Placement [Member]
Title of 12(b) Security
Title of 12(b) Security
Schedule of Segment Reporting Information, by Segment [Table]
Israel Ministry of Health [Member]
Israel Ministry of Health [Member]
Israel ministry of health.
Net operating loss and research and development credit carryforwards limitations on cumulative change in ownership minimum percentage.
Net Operating Loss And Research And Development Credit Carryforwards Limitations On Cumulative Change In Ownership Minimum Percentage
Net Operating Loss and Research and Development Credit Carryforwards Limitations On Cumulative Change In Ownership Minimum Percentage
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount
Stock-based compensation
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Weighted-Average Exercise Price, Forfeited/cancelled
Money Market Funds [Member]
Related and Nonrelated Parties [Domain]
Related Party
Income Tax Disclosure [Text Block]
Income Taxes
Income taxes.
Income Taxes [Line Items]
Income Taxes [Line Items]
Capitalized R&D
Deferred Tax Assets Capitalized Research and Development
Deferred tax assets capitalized research and development.
Equity Method Investment, Aggregate Cost
Investment in joint venture
Accrued Liabilities, Fair Value Disclosure
Accrued expenses
Other non-current liabilities
Other Liabilities, Noncurrent
Changes in assets and liabilities:
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]
Summary of Components of Property and Equipment, Net
Property, Plant and Equipment [Table Text Block]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Weighted-Average Exercise Price, Outstanding
Weighted-Average Exercise Price, Outstanding
Income Tax Disclosure [Abstract]
Fair Value, Recurring and Nonrecurring [Table]
Unrecognized Tax Benefits
Ending balance of unrecognized tax benefits
Beginning balance of unrecognized tax benefits
Unrecognized Tax Benefits
Additional Paid-in Capital [Member]
Additional Paid-In Capital [Member]
Stock Issued During Period, Value, Issued for Services
Common stock issued, value
Study Support Agreement [Member]
Study Support Agreement [Member]
Study support agreement.
Measurement Frequency [Domain]
Statement of Income Location, Balance [Axis]
Income Statement Location
Change in Accounting Principle, Accounting Standards Update, Adoption Date
Change in accounting principle, accounting standards update, adoption date
Trading Symbol
Trading Symbol
Property, Plant and Equipment Disclosure [Text Block]
Property and Equipment, Net
Dr. Padmanabh Chivukula [Member]
Dr. Padmanabh Chivukula.
Dr. Padmanabh Chivukula [Member]
Related Party Transaction [Table]
Schedule Of Related Party Transactions By Related Party [Table]
Subsequent Event Type [Axis]
Subsequent Event Type
Employee-related Liabilities, Current, Total
Employee-related Liabilities, Current
Accrued compensation
Financing activities
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term
Expected life (in years)
Recurring [Member]
Fair Value, Recurring [Member]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]
Accrued Liabilities Detail
Lessee, Operating Lease, Liability, to be Paid
Total remaining lease payments
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Less: imputed interest
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent
Tax credits - research and development credits percent
Tax credits - research and development credits percent
Equity Components [Axis]
Equity Components
Upfront payment to be received
Upfront Payment to be Received
Upfront payment to be received.
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term
Weighted-Average Remaining Contractual Term (Years), Exercisable and expected to vest - December 31, 2024
Contract With Customer Asset Deductions
Contract with customer asset deductions.
Deductions
Equity Component [Domain]
Equity Component
Asset Class [Axis]
Deferred Revenue, Noncurrent, Total
Deferred Revenue, Noncurrent
Deferred revenue, net of current portion
Deferred Tax Assets, Deferred Income
Deferred revenue
Document Annual Report
Document Annual Report
Payment received first installment.
Payment Received First Installment
Received first installment
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period
Share options expiration period
Depreciation, Depletion and Amortization, Nonproduction, Total
Depreciation, Depletion and Amortization, Nonproduction
Depreciation and amortization
Depreciation and amortization expenses
Statement of Comprehensive Income [Abstract]
Equity Method Investment, Nonconsolidated Investee [Axis]
Equity Method Investment, Nonconsolidated Investee
Maximum [Member]
Maximum [Member]
Statistical Measurement [Axis]
Statistical Measurement
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Weighted-Average Exercise Price, Exercised
Common Stock, Value, Issued
Common stock: $0.001 par value; 60,000 shares authorized; issued and outstanding shares were 28,414 at December 31, 2025 and 27,000 at December 31, 2024
Final payment of disbursement amount.
Final Payment Of Disbursement Amount
Final payment of disbursement amount
Option to extend initial term on an annual basis.
Option To Extend Initial Term On An Annual Basis
Option to extend initial term on an annual basis
Consolidation, Policy [Policy Text Block]
Basis of Presentation and Principles of Consolidation
CSL Seqirus [Member]
CSL Seqirus [Member]
CSL seqirus.
Equipment [Member]
Research equipment [Member]
Commitment and contingencies.
Commitment And Contingencies [Table]
Commitment And Contingencies [Table]
Deferred Tax Assets, Operating Loss Carryforwards, Total
Deferred Tax Assets, Operating Loss Carryforwards
Net operating loss
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]
Tax Credit Carryforward [Axis]
Tax Credit Carryforward
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent
State and local income taxes, net of federal income tax effect percent
Non-refundable payment received.
Non Refundable Payment Received
Non-refundable payment received
Entity Public Float
Entity Public Float
mRNA technology.
M R N A Technology [Member]
mRNA Technology [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Expected volatility
Permanent differences
Effective Income Tax Rate Reconciliation Other Permanent Differences
Effective income tax rate reconciliation other permanent differences.
Related Party Transaction [Line Items]
Related Party Transaction [Line Items]
Revenue from Contract with Customer [Text Block]
Revenue
Entity Registrant Name
Entity Registrant Name
Debt Disclosure [Text Block]
Debt
Entity Voluntary Filers
Entity Voluntary Filers
Customer Concentration Risk [Member]
Customer Concentration Risk [Member]
Accrued liabilities paid upon occurrence of specified events
Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized
Other Nonoperating Income (Expense), Total
Other Nonoperating Income (Expense)
Finance income, net
Additional Paid in Capital, Total
Additional Paid in Capital
Additional paid-in capital
State
Deferred State and Local Income Tax Expense (Benefit)
Subsequent Events [Abstract]
Cybersecurity Risk Management Positions or Committees Responsible [Flag]
SOFR [Member]
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]
Income Tax Expense (Benefit)
(Benefit) provision for income taxes
Provision for income taxes
Measurement Frequency [Axis]
Schedule of summary of significant accounting policies.
Schedule Of Summary Of Significant Accounting Policies [Table]
Schedule Of Summary Of Significant Accounting Policies [Table]
Proceeds from Issuance of Common Stock
Proceeds from issuance of common stock, net of issuance costs
Net proceeds from sales of common stock
Achieved development and regulatory milestone included accounts receivable
Achieved Development and Regulatory Milestone Included Accounts Receivable
Achieved development and regulatory milestone included accounts receivable.
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
LUNAR-CF, Net [Member]
LUNAR-CF, net.
LUNAR-CF, Net [Member]
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Concentration Risk, Credit Risk, Policy [Policy Text Block]
Concentration of Credit Risk and Significant Customers
The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. as well as trade accounts receivable, notes and loans receivable.
Prepaid Expenses And Other Receivables
Prepaid expenses and other current assets
Expiration of initial term.
Expiration Of Intial Term
Expiration of initial term
Payments to Acquire Property, Plant, and Equipment, Total
Payments to Acquire Property, Plant, and Equipment
Acquisition of property and equipment
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period
Restricted stock units granted
Assets
Total assets
Property, Plant and Equipment [Table]
Schedule Of Property Plant And Equipment [Table]
Income Tax Paid, State and Local, after Refund Received
Income Tax Paid, State and Local, after Refund Received, Total
State income taxes paid, net of (refunds) received
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term
Weighted-Average Remaining Contractual Term (Years), Exercisable - December 31, 2024
Directors Or Officers Except Chief Scientific Officer, Coo, Svp, CC and Pao [Member]
Directors or officers except chief scientific officer, coo, svp, cc and pao.
Directors or Officers Except Chief Scientific Officer, COO, SVP, CC and PAO [Member]
Collaboration Revenue [Member]
Collaboration revenue.
Share-Based Payment Arrangement [Policy Text Block]
Share-Based Compensation
Schedule of Accounts Receivable
Accounts and Nontrade Receivable [Text Block]
Total deferred income tax expense
Deferred Income Tax Expense (Benefit)
Equity method investment, sale of common stock
Sale of Stock, Number of Shares Issued in Transaction
Stock Issued During Period, Shares, New Issues
Issuance of common stock
Proceeds from issuance of common stock, net of issuance costs ( Shares)
Diluted
Earnings Per Share, Diluted
Earnings Per Share, Diluted, Total
Schedule of Segment Reporting Information, by Segment [Table Text Block]
Summary of Reported Segment Revenues, Segment Loss and Income, and Significant Segment Expenses
Long-Term Contract with Customer [Member]
Long-Term Contract with Customer [Member]
Title and Position [Domain]
Title of Individual
Disbursed amount upon execution of amendment.
Disbursed Amount Upon Execution Of Amendment
Disbursed amount upon execution of amendment
City Area Code
City Area Code
Underlying agreement.
Underlying Agreement [Member]
Underlying Agreement [Member]
Other Comprehensive Income (Loss), Net of Tax, Total
Other Comprehensive Income (Loss), Net of Tax
Other comprehensive loss
Auditor Name
Auditor Name
Fee payable
Debt Instrument, Fee Amount
Non-cash asset disposal
Non - Cash Asset Disposal
Non-Cash Asset Disposal
Debt Instrument, Face Amount
Term loan
Joint ventures, equity method investments and variable interest entities.
Joint Ventures Equity Method Investments And Variable Interest Entities Policy [Text Block]
Joint Ventures, Equity Method Investments and Variable Interest Entities
Stock issued during period shares under equity plan.
Stock Issued During Period Shares Under Equity Plan
Issuance of common stock under equity plans (in shares)
Deferred Tax Assets, Tax Credit Carryforwards, Total
Deferred Tax Assets, Tax Credit Carryforwards
Tax credits
Counterparty Name [Domain]
Counterparty Name
Tax credits - research and development credits
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
Legal accrual
Legal Accrual Current
Legal accrual current.
Operating Lease, Weighted Average Remaining Lease Term
Weighted-average remaining lease term (in years)
Segment Reporting Information [Line Items]
Effective Income Tax Rate Reconciliation Effects Of Cross Border Tax Laws Global Intangible Low Tax Income
Effective income tax rate reconciliation effects of cross-border tax laws global intangible low-tax income.
Effects of cross-border tax laws - Global intangible low-tax income
Cash and Cash Equivalents, Policy [Policy Text Block]
Cash and Cash Equivalents
Property, Plant and Equipment, Net
Property and equipment, net
Property and equipment, net
Foreign
Deferred Foreign Income Tax Expense (Benefit)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number
Number of Shares, Exercisable and expected to vest December 31, 2024
Operating Income (Loss)
Loss from operations
Loss from operations
Debt Instrument, Extended Term Period
Debt instrument, extended term period.
Extended term period
Retained Earnings [Member]
Accumulated Deficit [Member]
Disbursement payment upon achievement of required manufacturing practices and IND application.
Disbursement Payment Upon Achievement Of Required Manufacturing Practices And I N D Application
Disbursement payment upon achievement of required manufacturing practices and IND application
Share-Based Payment Arrangement, Noncash Expense, Total
Share-Based Payment Arrangement, Noncash Expense
Share-based compensation expense
Offering costs
Payments of Stock Issuance Costs
Operating Lease, Weighted Average Discount Rate, Percent
Weighted-average discount rate
Operating Lease, Liability, Noncurrent
Operating lease liability, net of current portion
Fair Value, Inputs, Level 1 [Member]
Level 1 [Member]
Class of Stock [Line Items]
Class Of Stock [Line Items]
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Net cash provided by (used in) financing activities
Grants Receivable
Grants Receivable
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]
Change in accounting principle, accounting standards update, adopted
Auditor Location
Auditor Location
Long-Term Debt [Member]
Long-term Debt [Member]
Effective income tax rate reconciliation nondeductible expense limitations on deductibility of officer Compensation percent.
Effective income tax rate reconciliation nondeductible expense limitations on deductibility of officer Compensation percent.
Limitations on the deductibility of officer compensation percent
Changes in unrecognized tax benefits percent
Effective Income Tax Rate Reconciliation Changes In Unrecognized Tax Benefits Percent
Effective income tax rate reconciliation changes In unrecognized tax benefits percent.
Effective Income Tax Rate Reconciliation Changes In Unrecognized Tax Benefits
Effective income tax rate reconciliation changes In unrecognized tax benefits.
Changes in unrecognized tax benefits
Grant Revenue [Member]
Grant [Member]
Income Tax Jurisdiction [Domain]
Income Tax Authority
Seqirus Inc [Member]
Seqirus, Inc [Member]
Seqirus, Inc.
Entity Interactive Data Current
Entity Interactive Data Current
LUNAR-COVID [Member]
LUNAR-COVID.
LUNAR-COVID [Member]
Deferred Tax Liabilities, Gross [Abstract]
Deferred tax liabilities:
Deferred revenue
Increase (Decrease) in Contract with Customer, Liability
Deferred revenue
Payments for Advance to Affiliate
Payments for advance
Statement of Income Location, Balance [Domain]
Income Statement Location
Operating activities
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]
Furniture and Fixtures [Member]
Office equipment and furniture [Member]
Contract With Customer Liability Additions For Advanced Billings
Contract Liabilities, Additions for advanced billings
Contract With Customer Liability Additions For Advanced Billings
Unbilled Receivables, Current
Unbilled accounts receivable
Accounts receivable, Balance
Accounts receivable, Balance
Contract with Customer, Asset, after Allowance for Credit Loss, Total
Contract with Customer, Asset, after Allowance for Credit Loss
Acquisition of research and development in process through issuance of common stock.
Acquisition Of Research And Development In Process Through Issuance Of Common Stock
Acquisition of in-process research and development through issuance of common stock
Revenue, practical expedient description
Revenue, Practical Expedient, Remaining Performance Obligation, Description
Grant receivable number of installments.
Grant Receivable Number Of Installments
Grant, number of installments
Disbursement period one.
Disbursement Period One [Member]
Disbursement Due January 2020 [Member]
Cumulative Effect, Period of Adoption [Domain]
Cumulative Effect, Period of Adoption
Line of Credit Facility, Current Borrowing Capacity
Revolving credit line available
Entity Tax Identification Number
Entity Tax Identification Number
Disbursement amount payable upon achievement of project goal.
Disbursement Amount Payable Upon Achievement Of Project Goal
Disbursement amount payable upon achievement of project goal
Revenue:
Revenues [Abstract]
Share Price
Fair value of common stock
Long-Term Debt, Type [Axis]
Long-term Debt, Type
Debt Instrument, Term
Term of agreement
Income Tax Authority, Name [Domain]
Grant two.
Grant Two [Member]
Grant 2 [Member]
Local Phone Number
Local Phone Number
Weighted Average Number of Shares Outstanding, Diluted [Abstract]
Weighted-average shares outstanding
Auditor Opinion [Text Block]
Auditor Opinion
Accrued cystic fibrosis foundation liability.
Accrued Cystic Fibrosis Foundation Liability
Cystic Fibrosis Foundation liability
Other collaboration agreements.
Other Collaboration Agreements [Member]
Other Collaboration Agreements [Member]
Accounting Policies [Abstract]
Disaggregation of Revenue [Line Items]
Disaggregation Of Revenue [Line Items]
Collaboration revenue
Revenue
Total revenue
Lessee, Operating Lease, Liability, to be Paid, Year Four
2029
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant
Number of shares available
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition
Weighted-average remaining service period
GRI Bio Inc.
GRI Bio Inc Member
GRI Bio [Member]
Stock, Class of Stock [Table]
Schedule Of Stock By Class [Table]
Entity Emerging Growth Company
Entity Emerging Growth Company
Tax Credit Carryforward, Name [Domain]
Tax Credit Carryforward, Name